Harmony Biosciences Holdings Inc
Chiusa
SettoreSettore sanitario
34.03 -1.22
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
33.49
Massimo
34.54
Entrata | 10M 32M |
|---|---|
Vendite | -28M 215M |
P/E Media del settore | 12.984 49.052 |
EPS | 0.786 |
Margine di Profitto | 15.084 |
Dipendenti | 293 |
EBITDA | -2.8M 49M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +43.64% upside |
Utili prossimi | 4 ago 2026 |
|---|
Capitalizzazione di Mercato | -22M 1.9B |
|---|---|
Apertura precedente | 35.25 |
Chiusura precedente | 34.03 |
Notizie sul Sentiment di mercato
By Acuity
100%
0%
325 / 342 Classifica in Healthcare
Harmony Biosciences Holdings Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
